摘要
The American College of Cardiology/American Heart Association defines resistant hypertension(RH)as a clinical blood pressure(BP)reading of>130/80 mmHg in patients taking three antihypertensive drugs,including a renin–angiotensin system inhibitor,a calcium channel blocker(CCB),and a diuretic at well-tolerated doses.1,2 It is reported from multiple population-based surveys that in the United States,there is an approximately 12%–15%prevalence of RH among adults diagnosed with hypertension.2 A prospective study demonstrates that 20%of people diagnosed with RH had primary hyperaldosteronism.3,4 In addition to the classic three antihypertensive drugs,spironolactone and mineralocorticoid are also administered for RH.However,with respect to the safety profile of spironolactone,it has been reported to have several side effects such as low testosterone production,menstrual irregularities,and excessively raised serum potassium levels,leaving the drug unfit for the longitudinal therapeutic purpose of treating RH.
